Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 17 5 2019
medline: 29 7 2021
entrez: 17 5 2019
Statut: ppublish

Résumé

Changes in relapse activity during secondary progressive multiple sclerosis (SPMS) need to be accurately characterized in order to identify patients who might benefit from continuing disease-modifying therapies. To describe relapse occurrence in patients with SPMS during long-term follow-up and assess its impact on disability worsening. This retrospective cohort study included 506 patients. We assessed the influence of relapses on time from SPMS onset to an Expanded Disability Status Scale score of 6 (EDSS 6), and on irreversible worsening of EDSS scores across different periods. The annualized relapse rate (ARR) decreased with patient's age (mean reduction of 43% per decade) and SPMS duration (mean reduction of 46% every 5 years). Post-progression relapses were associated with shorter time from secondary progressive (SP) phase onset to EDSS 6 (hazard ratio (HR) = 1.29, 95% confidence interval (CI) = (1.01, 1.64)). Relapse occurrence during the first 3 years and 3-5 years after SP onset was associated with an increased risk of irreversible EDSS worsening (OR = 3.12 (1.54, 6.31) and 2.04 (1.16, 3.58)). This association was no longer significant after 5 years. The occurrence of relapses was a marker of short-term disability progression during early SPMS, but did not have decisive impact in later SPMS.

Sections du résumé

BACKGROUND
Changes in relapse activity during secondary progressive multiple sclerosis (SPMS) need to be accurately characterized in order to identify patients who might benefit from continuing disease-modifying therapies.
OBJECTIVE
To describe relapse occurrence in patients with SPMS during long-term follow-up and assess its impact on disability worsening.
METHODS
This retrospective cohort study included 506 patients. We assessed the influence of relapses on time from SPMS onset to an Expanded Disability Status Scale score of 6 (EDSS 6), and on irreversible worsening of EDSS scores across different periods.
RESULTS
The annualized relapse rate (ARR) decreased with patient's age (mean reduction of 43% per decade) and SPMS duration (mean reduction of 46% every 5 years). Post-progression relapses were associated with shorter time from secondary progressive (SP) phase onset to EDSS 6 (hazard ratio (HR) = 1.29, 95% confidence interval (CI) = (1.01, 1.64)). Relapse occurrence during the first 3 years and 3-5 years after SP onset was associated with an increased risk of irreversible EDSS worsening (OR = 3.12 (1.54, 6.31) and 2.04 (1.16, 3.58)). This association was no longer significant after 5 years.
CONCLUSION
The occurrence of relapses was a marker of short-term disability progression during early SPMS, but did not have decisive impact in later SPMS.

Identifiants

pubmed: 31094285
doi: 10.1177/1352458519848090
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

924-935

Auteurs

Kevin Ahrweiller (K)

Department of Neurology, Rennes University Hospital, Rennes, France.

Chloé Rousseau (C)

Clinical Investigation Center (CIC-P) INSERM 1414, Department of Clinical Pharmacology, Rennes University Hospital, Rennes, France.

Emmanuelle Le Page (E)

Department of Neurology, Rennes University Hospital, Rennes, France/Clinical Investigation Center (CIC-P) INSERM 1414, Rennes University Hospital, Rennes, France/West Neuroscience Network of Excellence (WENNE), Rennes, France.

Emma Bajeux (E)

Department of Epidemiology and Public Health, Rennes University Hospital, Rennes, France.

Emmanuelle Leray (E)

Ecole des Hautes Etudes en Santé Publique (EHESP), Rennes, France.

Laure Michel (L)

Department of Neurology, Nantes University Hospital, Nantes, France.

Gilles Edan (G)

Department of Neurology, Rennes University Hospital, Rennes, France/Clinical Investigation Center (CIC-P) INSERM 1414, Rennes University Hospital, Rennes, France/West Neuroscience Network of Excellence (WENNE), Rennes, France.

Anne Kerbrat (A)

Department of Neurology, Rennes University Hospital, Rennes, France/West Neuroscience Network of Excellence (WENNE), France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH